Skip to content
Axcess News – Lifestyle
Author:
BioAdaptives Inc.
UFC Hall of Famer Michael Bisping Backs Xycota Biosciences’ Low-Dose Psilocybin Research on PTSD and Concussion
November 12, 2026
BioAdaptives Acquisition Target Xycota Biosciences Launches Free PTSD Tactical & Support Hub for Veterans and First Responders Alongside At-Home Psilocybin Research
November 12, 2026
BioAdaptives Highlights Michael Bisping’s MyndMed(TM) Routine in UFC 331 Pre-Show Instagram Video
September 23, 2026
BioAdaptives Confirms First Commercial Orders of XcellaraHeart(TM) and Outlines Capital Restructuring Progress
September 3, 2026
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
August 17, 2026
BioAdaptives, Inc. Announces CEO’s Share Cancellation and Provides Capital Restructure Update
August 13, 2026
BioAdaptives Inc. Introduces XcellaraHeart(TM): the World’s First Stem Cell Mobilizer with a Targeted Cardiac Homing Signal
August 12, 2026
BioAdaptives Inc. Opens Commercial Ordering Window for XcellaraHeart(TM) Cellular Wellness Formula
August 3, 2026
BioAdaptives Inc. Eliminates Major Market Overhang by Retiring the Debt of the Largest Convertible Commercial Investor
July 30, 2026
BioAdaptives Inc. Reports Scaling of E-Commerce Footprint and Consumer Reach for MyndSystem(TM) Nootropic Platform
July 29, 2026
1
2
Next Page
→